The Intrinsic Value Valuation Methodology
Is there a mathematical justification for this price?
The Sam Finn Valuation Model estimates a company's Intrinsic Value using its reported financial fundamentals and compares it with the market price. The objective is to identify potential overvaluation and undervaluation, providing investors with a consistent framework for evaluating businesses beyond market sentiment and short-term expectations.
The Principles Behind Our Methodology
Sam Finn Reports' valuation model is built around a simple objective: estimating a company's fundamental value independently of short-term market expectations.
Our approach draws on three key principles.
Finding the Signal Behind the Noise
Imagine a large jar filled with thousands of jelly beans. Ask a hundred people to independently estimate how many it contains, without knowing or being influenced by anyone else's guess.
The answers will vary widely. Some will underestimate, others will overestimate, sometimes dramatically.
Yet when these independent estimates are combined, their average can come remarkably close to the actual number. This phenomenon is known as the Wisdom of Crowds.
The independence of these estimates is important. When individual errors are not systematically biased or correlated, they can offset one another, allowing the collective estimate to approach the actual value.
But financial markets are different.
Investors do not make their decisions in isolation. They observe market prices, follow analysts, react to news, and influence one another. As a result, their expectations can become correlated, sometimes driving market prices far above or below what the underlying business fundamentals might justify.
In other words, the market price does not necessarily represent the wisdom of independent judgments. At times, it may reflect the collective influence of optimism, pessimism, or prevailing market sentiment.
Sam Finn Reports applies a related statistical principle to business valuation.
Rather than treating the current market price as a reliable measure of a company's worth, our proprietary model analyzes financial fundamentals and their historical relationships to estimate a long-term equilibrium value — the Intrinsic Value (IVP).
The objective is to identify the underlying valuation level beneath short-term market fluctuations, allowing investors to measure how far the market price has deviated from the company's estimated fundamental value.
Zero-Growth Assumption
Imagine owning a small business that consistently earns €100,000 per year.
Now suppose its earnings never grow. Not next year, not in ten years, not even in fifty years. The business simply maintains its current earning power indefinitely.
Would that business still have value?
Of course. Even without growth, a profitable business can generate substantial value for its owners.
This is the principle behind our zero-growth assumption.
The IVP calculation assumes no additional future earnings growth. It uses the company's current earning power as a maintained baseline, subject to the model's other valuation assumptions.
In other words, future earnings growth is not required to justify the estimated intrinsic value.
This creates an important distinction between the value of a business as it stands today and the additional value that future growth might create.
Rather than depending on optimistic growth forecasts, the model establishes a valuation benchmark based on the company's existing earning power.
Mean Reversion and the Law of Large Numbers
Imagine flipping a fair coin ten times.
You might get heads eight times and tails only twice. That would give heads an 80% share of the results, even though the probability of heads on any individual flip is exactly 50%.
Now imagine flipping the same coin 10,000 times.
As the number of independent flips increases, the proportion of heads is increasingly likely to approach 50%.
This illustrates the Law of Large Numbers, a fundamental principle of probability theory.
It explains why short-term observations can differ significantly from their expected value, while averages tend to become more stable as the number of observations increases.
A related but distinct concept is Mean Reversion — the tendency of certain variables to move back toward their long-term average following unusually high or low observations.
Consider a rubber band stretched away from its resting position. The further it stretches, the greater the tension pulling it back.
In economics, competition and market forces can create similar tendencies toward equilibrium. When businesses earn unusually high profits, competitors are attracted to the opportunity, potentially putting pressure on profit margins. When market prices move significantly away from fundamental values, investors seeking attractive opportunities may help narrow those differences.
These forces resemble Adam Smith's concept of the invisible hand, where individual decisions and competition can contribute to broader market adjustments.
Unlike a rubber band, however, financial markets have no mechanical force guaranteeing a return to any particular value. Equilibrium is a tendency to be studied, not a certainty.
Sam Finn Reports applies the principle of mean reversion to fundamental valuation.
Unlike approaches that rely on historical valuation multiples, the Sam Finn Valuation Model does not redefine equilibrium based on past market valuations. Instead, equilibrium is determined by the relationship between market price and estimated Intrinsic Value (IVP), which is derived independently from a company's financial fundamentals.
Valuation equilibrium is always 100%, regardless of historical market valuations.
Even if a company has traded at an average Valuation of 180% for a decade, its theoretical equilibrium remains at 100%. Prolonged overvaluation does not become fair valuation simply because it has persisted. Similarly, prolonged undervaluation does not establish a new, lower equilibrium.
“This time it’s different!” — Actually, it’s not.
Market prices may rise far above or fall significantly below Intrinsic Value, sometimes for extended periods. However, the model's underlying hypothesis is that Valuation tends to return toward its fundamental equilibrium of 100% over the long term.
This convergence can occur through changes in market price, changes in Intrinsic Value, or a combination of both. The model's estimates and underlying assumptions must nevertheless remain subject to reassessment when significant changes in a company's fundamentals or business structure warrant it.
The Law of Large Numbers provides a statistical perspective on how broader observations can help reveal underlying patterns in the valuation of a company's earning power. Mean Reversion provides a related but distinct hypothesis that Valuation may tend toward its fundamental equilibrium of 100% over time.
Together, these principles form part of the statistical reasoning behind our valuation framework. They do not guarantee that market prices will return to equilibrium within any particular timeframe.
Mean reversion is a separate hypothesis about how market prices may develop relative to IVP. The valuation-adjusted ECT and CAGR calculations instead reflect the price paid for the company's estimated earning power and do not require market prices to return to equilibrium.
Seven ways to read the result.
Est. Intrinsic Value (IVP)
Intrinsic Value (IVP) represents the model's estimate of a company's fundamental value per share, derived from its reported financial statements.
IVP serves as a theoretical valuation equilibrium — a benchmark against which the current market price can be evaluated. As a company's financial fundamentals improve or deteriorate, its estimated Intrinsic Value changes accordingly.
Unlike a conventional price target, IVP does not predict where a stock will trade at a specific future date. Instead, it provides a fundamental valuation benchmark that helps investors assess potential future returns.
By comparing the market price (P) with IVP, investors can identify potential overvaluation or undervaluation. IVP also forms the foundation for the model's other valuation and return metrics.
Valuation
Valuation measures the relationship between a security's current market price (P) and its estimated Intrinsic Value (IVP). It indicates whether the security is trading above, below, or at its theoretical valuation equilibrium.
Valuation = P / IVP × 100%
Below 100% – Undervalued: The market price is below estimated Intrinsic Value.
100% – Equilibrium: The market price equals estimated Intrinsic Value.
Above 100% – Overvalued: The market price exceeds estimated Intrinsic Value.
Valuation can change for two fundamentally different reasons: changes in market price (P) or changes in Intrinsic Value (IVP).
A decrease in Valuation caused by a falling share price is very different from a decrease caused by rising IVP. When a company's financial fundamentals improve, its Intrinsic Value may increase, reducing Valuation even if the share price remains unchanged or continues to rise. This represents an improvement in the company's fundamental value rather than a decline in its market price.
Under the model's equilibrium assumption, a financially healthy company can experience sustained share price appreciation as its Intrinsic Value grows, while Valuation remains relatively stable near 100%. In such a case, a long-term Valuation chart may appear almost horizontal even as the share price rises substantially.
This distinction is essential: a rising share price does not necessarily indicate increasing overvaluation. What matters is how the price develops relative to the company's underlying Intrinsic Value.
Purchasing below IVP provides more estimated earning power per dollar invested, increasing the model's theoretical return potential. A subsequent rise in Valuation toward equilibrium may also contribute to realized price appreciation. Conversely, paying above IVP reduces the earning power acquired per dollar, while a declining valuation premium may further affect realized returns.
However, a security may trade above or below its estimated Intrinsic Value for valid reasons. Valuation should therefore be interpreted alongside the company's business prospects, financial condition, and risks rather than as an automatic buy or sell signal.
Estimated Cycle Time
Estimated Cycle Time (ECT) represents the theoretical number of years required for an investment to double in total wealth under the model's assumptions, using estimated Intrinsic Value (IVP) as the purchase-price benchmark.
The metric is derived from the company's underlying financial fundamentals and reflects its estimated normal return potential at 100% Valuation. It excludes the effect of purchasing above or below IVP and any additional gains or losses arising from changes in the valuation relationship.
Connecting Public and Private Business Valuation
When purchasing an entire business, investors often consider a straightforward question: how many years would it take for the business to generate earnings equivalent to the purchase price?
Buying a share means acquiring a proportional ownership interest in that same business and its earning power.
ECT brings a comparable time-based perspective to publicly traded companies. Under the model's zero-growth assumption, earning power is assumed to remain constant, and the model expresses the resulting theoretical wealth accumulation period in years.
At valuation equilibrium, IVP provides the purchase-price benchmark. The separate metric, Estimated Cycle Time Including Valuation, adjusts this baseline for the actual market price paid.
Interpreting ECT
An ECT of 5 years indicates that, under the model's assumptions, the business can generate value equivalent to the initial investment over approximately five years. If the original investment retains its value and the accumulated value accrues to the shareholder, total investment wealth would theoretically double.
This accumulated value may be reflected in distributions to shareholders, the value of retained earnings, or a combination of both. ECT therefore refers to theoretical total wealth accumulation, rather than share-price appreciation alone.
ECT is based on the model's zero-growth assumption, meaning that additional future earnings growth is not required in the underlying calculation. This is a calculation assumption, not a guarantee that earning power will remain stable.
Actual improvements or deterioration in the company's fundamentals, and how the company distributes or uses its earnings, may affect the outcome.
ECT is not a literal acquisition payback period, a forecast of when a stock price will double, or a measure of the duration of a stock market cycle. It provides a standardized measure of theoretical normal return potential.
The shorter the ECT, the higher the corresponding theoretical annualized return. Conversely, a longer ECT indicates a lower corresponding return.
Estimated Annualized Return (CAGR)
Estimated Annualized Return (CAGR) represents the theoretical annualized rate of return derived from the company's Estimated Cycle Time (ECT), using estimated Intrinsic Value (IVP) as the purchase-price benchmark.
While ECT expresses the theoretical time required for total investment wealth to double under the model's assumptions, CAGR translates that timeframe into an equivalent compounded annual rate, making it easier to compare the theoretical return potential of different companies.
Estimated Annualized Return (CAGR) = (2^(1 / ECT) − 1) × 100%
For example, an ECT of 5 years corresponds to a theoretical annualized return of approximately 14.9%. A constant compounded annual return of 14.9% would produce the same doubling of investment wealth over five years.
A Smoothed Return Model
The calculation expresses the model's theoretical wealth accumulation over the estimated cycle time as an equivalent constant compounded annual rate.
This does not mean that the company's earnings or the investor's wealth are assumed to grow at that constant rate. Under the zero-growth assumption, earning power remains constant; CAGR simply expresses the theoretical beginning-to-end change in investment wealth in annualized form.
Actual returns may vary substantially from year to year. The metric does not forecast the path of share prices, distributions, or annual investment returns.
Return Potential at Valuation Equilibrium
Like baseline ECT, baseline CAGR uses 100% Valuation as its purchase-price benchmark. It excludes the effect of purchasing above or below IVP and any additional gains or losses arising from changes in the valuation relationship.
The estimate is based on the model's zero-growth assumption and does not require additional future earnings growth. This is a calculation assumption, not a guarantee of stable earning power.
The theoretical doubling of wealth assumes that the original investment retains its value and that the accumulated value accrues to the shareholder. Actual outcomes depend on how business earnings translate into shareholder wealth through distributions and the value of retained earnings.
Changes in the company's financial fundamentals may alter both IVP and baseline ECT, affecting the corresponding theoretical annualized return.
A higher estimated CAGR does not automatically make a security a better investment. The current market valuation, business risks, and sustainability of the company's earning power must also be considered.
To account for the current market price relative to Intrinsic Value, the model provides a separate metric: Estimated Annualized Return (CAGR) Including Valuation.
The price you pay changes the estimated return.
Estimated Cycle Time Including Valuation
Estimated Cycle Time Including Valuation adjusts the company's baseline Estimated Cycle Time (ECT) for the price paid relative to its estimated Intrinsic Value (IVP).
The underlying principle is straightforward: buying a share means acquiring an ownership interest in a business and its earning power. Under the model's zero-growth assumption, that earning power is assumed to remain constant. Paying less for the same earning power shortens the theoretical time required to accumulate value equivalent to the purchase price. Paying more lengthens it.
Estimated Cycle Time Including Valuation = ECT × Valuation
Valuation is expressed as a decimal (e.g., 80% = 0.80).
The Impact of Undervaluation and Overvaluation
At 80% Valuation, an investor pays 20% less than estimated Intrinsic Value for the same underlying earning power. The model therefore reduces the baseline cycle time by 20%.
This lower purchase price provides greater earning power per dollar invested. The resulting return advantage does not require the market price to rise toward IVP.
Conversely, purchasing at 120% Valuation means paying 20% more than estimated Intrinsic Value for the same earning power. The adjusted cycle time is therefore 20% longer.
At 100% Valuation, the adjusted cycle time equals the baseline ECT.
Practical Example
Consider a company with a baseline ECT of 5 years, assuming its underlying earning power remains unchanged:
| Valuation | Adjusted Cycle Time | Price Paid Relative to IVP |
|---|---|---|
| 50% | 2.5 years | 50% discount |
| 80% | 4 years | 20% discount |
| 100% | 5 years | At estimated Intrinsic Value |
| 120% | 6 years | 20% premium |
| 150% | 7.5 years | 50% premium |
Two investors can therefore acquire the same underlying earning power at different prices and obtain different theoretical return potential, even when the company's fundamentals are identical.
What Happens When the Price Returns to Equilibrium?
If the market price rises toward IVP while the company's fundamentals remain unchanged, the discount available to a new buyer diminishes. At 100% Valuation, the undervaluation-related return advantage is no longer available at the current price, and the adjusted cycle time returns to the baseline ECT.
An investor who purchased at the lower price retains that original purchase price and benefits from the price appreciation. However, the return potential available on the investment's current market value now reflects the higher valuation.
A Theoretical Estimate
The adjusted cycle time translates the purchase price and the company's estimated earning power into a standardized measure of theoretical return potential.
It does not forecast the timing of a market correction or guarantee when an investment will double in value. Translating business earnings into investor wealth depends on how those earnings are distributed, retained, and used by the company.
The zero-growth assumption is a calculation assumption, not a guarantee of stable earnings. Changes in the company's financial fundamentals may alter both IVP and the baseline ECT.
Estimated Annualized Return (CAGR) Including Valuation
Estimated Annualized Return (CAGR) Including Valuation represents the theoretical annualized return potential of an investment after accounting for both the company's underlying financial fundamentals and its current market valuation.
While the baseline CAGR reflects the company's estimated normal return potential at valuation equilibrium, the adjusted metric reflects how paying more or less for the same underlying earning power changes the model's theoretical annualized return.
Estimated Annualized Return (CAGR) Including Valuation = (2^(1 / (ECT × Valuation)) − 1) × 100%
Valuation is expressed as a decimal (e.g., 80% = 0.80).
Why the Purchase Price Matters
A fundamentally strong company is not necessarily an attractive investment at any price.
When a security trades below its estimated Intrinsic Value, the investor acquires the same underlying earning power at a lower price. Under the model's zero-growth assumption, this shortens the adjusted cycle time and increases the corresponding theoretical annualized return. This return advantage does not require the valuation discount to narrow.
Conversely, purchasing at a valuation premium means paying more for the same underlying earning power. This lengthens the adjusted cycle time and reduces the corresponding theoretical annualized return.
This distinction is particularly important when comparing companies. A business with strong financial fundamentals may offer a lower estimated investment return than a more moderately performing business purchased at a sufficiently attractive valuation.
Practical Example
Consider a company with a baseline Estimated Cycle Time (ECT) of 5 years, corresponding to a normal estimated annualized return of approximately 14.9%.
| Valuation | ECT Including Valuation | CAGR Including Valuation |
|---|---|---|
| 50% | 2.5 years | 32.0% |
| 80% | 4 years | 18.9% |
| 100% | 5 years | 14.9% |
| 120% | 6 years | 12.2% |
| 150% | 7.5 years | 9.7% |
The company's underlying earning power and baseline ECT remain unchanged in this example. The differences in theoretical annualized returns arise entirely from the price paid relative to Intrinsic Value.
A Smoothed Estimate, Not a Guaranteed Return
The calculation converts the adjusted cycle time into the constant compounded annual rate that would correspond to a doubling of investment wealth over that period. It expresses the model's theoretical return potential in a standardized annualized form; it does not assume that actual returns occur at a constant rate.
The calculation does not require valuation to return to equilibrium. If the market price moves toward IVP while fundamentals remain unchanged, the return potential available at the new market price changes accordingly.
Actual investor returns depend on how business earnings translate into shareholder wealth through distributions and the value of retained earnings. Changes in the company's financial fundamentals may also alter IVP and the baseline ECT.
The metric therefore supports consistent comparisons between investment opportunities, but does not predict actual annual returns or guarantee when an investment will double in value.
Tested across 26 years and 107 quarters.
Berkshire Hathaway provides a compelling historical case study for the Sam Finn Valuation Model. Its extensive financial history and long-standing commitment to value investing under Warren Buffett make it a particularly relevant company for examining the relationship between market price and estimated Intrinsic Value (IVP).
The crucial distinction is that IVP is calculated independently of market price.
The model derives Intrinsic Value solely from reported financial fundamentals, without using the company's share price as an input. Yet across 107 quarterly observations spanning more than 26 years, estimated Intrinsic Value and Berkshire Hathaway's actual market price have followed remarkably similar historical paths.
The following charts and statistical results examine this relationship from three perspectives: the long-term correspondence between IVP and market price, the correlation between their quarterly percentage changes, and the historical fluctuations of Valuation (P/IVP) around the model's 100% fundamental equilibrium.
Across 107 quarterly observations, the regression analysis shows a remarkably strong linear relationship between Berkshire Hathaway's market price and the model's independently calculated Intrinsic Value (IVP).
However, part of this relationship may reflect the long-term upward trend shared by both series.
To examine the relationship beyond the long-term trend, we also compared quarter-over-quarter percentage changes in IVP and market price.
The resulting correlation of 0.5892 indicates a meaningful positive relationship between their quarterly movements, providing additional evidence that the association extends beyond their shared long-term growth.
- R² (coefficient of determination)
- 0.9634
- Observations
- 107
- Slope (t-stat)
- 0.8984 (52.57)
- p-value
- 3.01 × 10⁻⁷⁷
- Pearson Correlation (r)
- 0.5892
- Observations (quarterly changes)
- 106
- Market price (P)
- $510.37
- Intrinsic Value (IVP)
- $570.30
- Valuation (P/IVP)
- 89%
- Margin of Safety
- 12%
- ECT / CAGR
- 6.3 yrs / 12%
- ECT incl. valuation / CAGR
- 5.6 yrs / 13%
What the Evidence Tells Us
The Berkshire Hathaway case study demonstrates a remarkably strong historical relationship between market price and Intrinsic Value (IVP), even though IVP is calculated independently from financial fundamentals without using market prices as an input.
The relationship is evident not only in the long-term development of both series but also in their quarterly percentage changes. Meanwhile, the Valuation chart illustrates how market prices have fluctuated relative to the model's fundamental equilibrium of 100%.
Together, these findings provide encouraging historical evidence supporting the relevance of the Sam Finn Valuation Model as a framework for assessing market valuations.
Berkshire Hathaway's share repurchases provide another perspective on the relationship between market price and estimated Intrinsic Value. Their timing relative to the model's valuation estimates is examined in our 26-year Berkshire Hathaway study.
However, historical relationships do not guarantee future performance, and the results should not be interpreted as predictions of future share prices or the timing of a return to valuation equilibrium.
Historical statistical fit does not guarantee future accuracy or returns. Not investment advice.
Case NIKE
The Anatomy of a Bubble and the Return to Equilibrium
1. Identifying bubbles with the model
Valuation bubbles do not appear out of nowhere, and they do not form overnight. They usually take years of excessive optimism, during which the market price drifts away from the company's underlying earning power. The Berkshire Hathaway case shows how price and Intrinsic Value move together in a stable environment. Nike (NKE) shows how the model can identify the formation of a massive valuation bubble, its peak and its eventual deflation.
2. A long era of equilibrium (1996–2013)
For almost two decades, from 1996 to around 2013, Nike's market price and IVP tracked each other remarkably closely. In Q2/1996 the price was about $3.66 against an IVP of $4.00 (Valuation ~92%). In Q1/2000 the price was $6.15 against an IVP of $6.11 (Valuation 100.7%).
Throughout this period, Valuation fluctuated around the 100% equilibrium line, just as the model would expect.
3. Decoupling and the formation of the bubble (2014–2020)
After 2014 the relationship began to change. The market price accelerated well beyond the growth of Intrinsic Value. By 2018 Valuation had already reached about 200%, and by 2020 the price was approaching $100 while IVP stood at about $24, a Valuation of almost 400%.
Nike's business was in excellent shape, and baseline ECT improved to 1.75 years in Q2/2020. Yet the valuation had moved far beyond what the fundamentals could justify.
4. Turning point in Q4/2020: weaker fundamentals, peak valuation
At the end of 2020 the fundamentals took a hit: baseline ECT lengthened from 1.75 years to 2.54 years, and further to 2.71 years in Q1/2021. The market did not slow down, and the price kept climbing toward its peak of about $167.
Valuation stretched to an extreme: in Q2/2021 it reached 491.9%, meaning investors were paying roughly five times the model's estimated Intrinsic Value.
This showed up directly in every other metric: the Valuation Premium fell to about −80%, ECT Including Valuation stretched from 2–3 years to 14.4 years, and CAGR Including Valuation dropped below 5% (4.9%), even though the company's baseline earning power remained solid.
5. The air leaks out (2021–2025)
As the bubble began to deflate, the share price entered a multi-year decline. Notably, Nike's business and Intrinsic Value actually recovered and stabilized at around $37–40 between 2021 and 2025.
Even that did not help. Once the stock had been bought at five times its Intrinsic Value, stable fundamentals could not stop the decline. The air kept leaking out of the bubble.
6. Back to equilibrium (2026–2027)
After a long correction, market price and Intrinsic Value have met again. In Q1/2027 the price ($38.48) sits slightly below the estimated IVP ($42.73). Valuation is back near equilibrium at 90.0%, the negative Valuation Premium has turned into a small Margin of Safety (+11.1%), and ECT Including Valuation (3.37 years) and CAGR Including Valuation (22.8%) have returned to levels in line with the company's earning power.
The case illustrates the core lesson of the model: even for a high-quality company, the price paid determines the return potential. The model's metrics flagged the extreme overvaluation years before it unwound.
Pin up to 3 charts to move them to the top for comparison.
Nike (NKE) · quarterly observations Q2/1996 – Q1/2027 on Nike's fiscal-year calendar (fiscal year ends in May; Q1/2027 covers June–August 2026) · move the cursor over any chart to follow the same quarter in all charts.
Historical model outputs do not guarantee future accuracy or returns. Not investment advice.
Transparent outputs, protected calculations.
The model's underlying principles, financial metrics, historical evidence, and limitations are explained throughout this methodology. However, the proprietary formulas, parameters, transformations, and weighting methods used to derive the results remain confidential.
- Reported information can be incomplete, revised or affected by accounting choices.
- Structural business changes can make historical relationships less useful.
- Market price can remain above or below model value for extended periods.
- The model is only one part of investment analysis. Investors must conduct their own due diligence, including assessing business prospects and risks. No model guarantees future returns.
- Historical relationships do not guarantee future performance or the accuracy of future valuation estimates.
Ready to see what the model says about real companies?
Every report applies this exact framework — Intrinsic Value, Valuation and Expected CAGR, updated quarterly.
Includes free sample reports for Berkshire Hathaway and Nike